A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 327 (planned)
- Started
- Feb 27, 2025
- Main results expected
- Feb 15, 2029
- Fully finished
- Feb 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience an Adverse Event (AE)
Measured over: Up to approximately 44 months
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Measured over: Up to approximately 3 weeks
Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 44 months
Part 1: Objective Response Rate (ORR)
Measured over: Up to approximately 44 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06780137 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC